Multi-cancer early detection (MCED) blood test

About Flomics

Founded in 2015, Flomics is a private, pre-revenue diagnostics company pioneering an RNA-based liquid biopsy platform. Its technology combines optimized NGS protocols for cfRNA with proprietary bioinformatics and AI to detect cancer and other complex diseases from a blood sample. The company also offers end-to-end genomics services for research partners while advancing its own multi-cancer screening test toward clinical validation.

Therapeutic Areas